Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 7Thoracic 3Gynecologic 3Dermatologic 3Sarcoma 2Genitourinary 2Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 52Kidney Neoplasms 43Melanoma 23Neoplasm Metastasis 14Uterine Cervical Neoplasms 8Breast Neoplasms 5Vaginal Neoplasms 4Penile Neoplasms 4Pancreatic Neoplasms 4Oropharyngeal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Anus Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Merkel Cell 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Testicular Germ Cell Tumor 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Wilms Tumor 1

Interventions

pembrolizumab 33Nivolumab 15atezolizumab 9Cyclophosphamide 7Paclitaxel 6Ipilimumab 6spartalizumab 5fludarabine 5Docetaxel 5durvalumab 4avelumab 4Immune Checkpoint Inhibitors 4Carboplatin 4olaparib 3cemiplimab 3cabozantinib 3Specimen Handling 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Interleukin-2 3Gemcitabine 3Fluorouracil 3Cisplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2obinutuzumab 2lenvatinib 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × aldesleukin × Genitourinary × Clear all
NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
12 enrolled
BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

PACT Pharma, Inc.

Phase 1 Suspended
21 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡